¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute hepatitis B without delta- agent with hepatic coma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • antiasthmatic agent
    Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antiinflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • antiviral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×¹ÙÀÌ·¯½º¹°Áú
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • agent
    1. ¹°Áú 2. ÀÎÀÚ 3. -¾à, -Á¦
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • biologic agent
    »ý¹°ÇÐÀûÁ¦Á¦
  • bacteriostatic agent
    Á¤±ÕÁ¦
  • blocking agent
    Â÷´ÜÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • curariform agent
    Äí¶ó·¹À¯»çÁ¦
  • curing agent
    °æÈ­Á¦
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • dehydrating agent
    Å»¼öÁ¦
  • denaturizing agent
    º¯¼ºÁ¦
  • depolarizing agent
    Å»ºÐ±ØÁ¦
  • diagnostic agent
    Áø´Ü¾à
  • diluting agent
    Èñ¼®Á¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • fibrinolytic agent
    ¼¶À¯¼Ò¿ëÇØ¹°Áú
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • germicidal agent
    »ì±ÕÁ¦
  • health care agent
    °Ç°­°ü¸®¿ä¿ø, °Ç°­°ü¸®±â±¸
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Hepatic vein
    °£Á¤¸Æ(ÊÜð¡Øæ)
  • ammonia, in hepatic encephalopathy
    ¾Ï¸ð´Ï¾Æ, °£¼º ³úº´Áõ(ÊÜàõ ÒàÜ»ñø)
  • hepatic
    °£(¼º)ÀÇ
  • hepatic
    °£(ÀÇ), °£(¼º)(ÊÜ)
  • hepatic abscess
    °£³ó¾ç(ÊÜÒÛåË).
  • hepatic abscess
    °£³ó¾ç(°£³ó¾ç).
  • hepatic adenoma
    °£¼±Á¾(ÊÜàÍðþ)
  • hepatic afferent veins
    °£µéÁ¤¸Æ
  • hepatic amebiasis
    °£¾Æ¸Þ¹ÙÁõ.
  • hepatic amyloidosis
    °£¾Æ¹Ð·ÎÀ̵åÁõ.
  • hepatic antrum
    °£µ¿±¼
  • hepatic apoplexy
    °£Á¹Áß(ÊÜðïñé).
  • hepatic artery
    °£µ¿¸Æ.
  • hepatic artery
    °£µ¿¸Æ(ÊÜÔÑØæ)
  • hepatic ascites
    °£¼ºº¹¼ö.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • subclinical hepatitis B
    ¹«Áõ»ó(ÙíñøßÒ) B Çü°£¿°
  • suppurative hepatitis
    È­³ó¼º °£¿°(¡­ÊÜæú).
  • suppurative hepatitis
    È­³ó¼º °£¿°(¡­ÊÜæú)
  • toxic hepatitis
    µ¶¼º°£¿°(Ô¸àõÊÜæú)
  • toxipathic hepatitis
    µ¶¹°¼º °£¿°(Ô¸ÚªàõÊÜæú).
  • transfusion hepatitis
    ¼öÇ÷°£¿°(¡­ÊÜæú).
  • trophopathic hepatitis
    ¿µ¾çÀå¾Ö¼º °£¿°(ç½å×î¡äôàõÊÜæú)
  • viral hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿°
  • viral hepatitis =virus h.
    ¹ÙÀ̽º¼º °£¿° (¡­àõÊÜæú).
  • virus hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿°(¡­ÊÜæú).
  • ammonia, in hepatic encephalopathy
    ¾Ï¸ð´Ï¾Æ, °£¼º ³úº´Áõ(ÊÜàõ ÒàÜ»ñø)
  • cardiac sclerosis,hepatic
    °£ °æÈ­Áõ(ÊÜÌãûùñø)
  • cholecysto-hepatic flexure adhesion syndrome
    ´ã³¶°áÀå°£°îºÎ À¯ÂøÁõÈıº(´ã³¶°áÀå°£°îºÎÀ¯ÂøÁõÈıº).
  • common hepatic artery
    ¿Â°£µ¿¸Æ
  • common hepatic artery<³ª> arteria hepatica com munis
    ÃѰ£µ¿¸Æ(õÅÊÜÔÑØæ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
TCRD T-cell receptor delta
EA   1) Esophageal Atresia
  Types
  1. Esophageal Atresia with Dis...
NYHA New York Heart Association
  Heart Disease¿¡ ´ëÇÑ Functional Classification
 &nbs...
; sine without; ~¿Ü¿¡
AWOL absent without official leave
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
EHBF Effective hepatic blood flow
EHBF Estimated hepatic blood flow
EHBA Extra Hepatic Biliary Atresia
FHF Fulminant Hepatic Failure
FHNC Functional Hepatic Nitrogen Clearance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute bulbar polioencephalitis
    ±Þ¼º ¿¬¼öȸ¹é³ú¿°
  • acute candidosis
    ±Þ¼º ĵµð´ÙÁõ
    Ä­µð´Ù¼ÓÀÇ ±ÕÀ¸·Î ÀÎÇÑ ±Þ¼º°¨¿°º´.
  • acute care bed
    ÀÀ±Þ Ä¡·á º´»ó
  • acute catarrhal laryngitis
    ±Þ¼º īŸ¸£ Èĵο°, ±Þ¼º īŸ¸£¼º Èĵο°
  • acute cellular rejecion
    ±Þ¼º ¼¼Æ÷¼º °ÅºÎ
    ÀϹÝÀûÀ¸·Î ÀÌ½Ä ÈÄ ¼ö °³¿ù ³»¿¡ ¹ß»ýÇϸç Ç÷û Å©·¹¾ÆÆ¼´ÑÄ¡°¡ »ó½ÂÇÏ°í ±Þ¼º ½ÅºÎÀüÀÇ ÀÓ»óÁõ»óÀ» µ¿¹ÝÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â °£Áú³» ´ÜÇÙ¼¼Æ÷ ħÀ±ÀÌ ¸Å¿ì °­ÇÏ°Ô ³ªÅ¸³ª¸ç, ºÎÁ¾ ¹× °æµµÀÇ °£Áú³» ÃâÇ÷À» º¸À̴µ¥ »ç¶÷ÀÇ °æ¿ì ´ÜÇÙ¼¼Æ÷´Â ÁÖ·Î Áß°£ Å©±â¿Í ÀÛÀº ¸²ÇÁ±¸·Î ±¸¼ºµÇ¾î ÀÖ°í dzºÎÇÑ È£¿°±â¼º ¼¼Æ÷Áú°ú ¼öÆ÷¼º ÇÙÀ» °¡Áø ¼Ò¼öÀÇ ÇüÁú¼¼Æ÷ ħÀ±µµ º¼ ¼ö ÀÖ´Ù.
  • acute cerebral anemia
    ±Þ¼º ³ú ºóÇ÷
  • acute cholecystitis
    ±Þ¼º ´ã³¶¿°
    ¼¼±Õ °¨¿°¿¡ ÀÇÇØ »ý±â°í °æ·Î´Â »óÇ༺
  • acute closed lock
    ±Þ¼º Æó±¸¼º °úµÎ°É¸²
    µ¿Åë¾øÀÌ 25~30mm
  • acute coalescent mastoiditis
    ±Þ¼º À¶ÇÕ À¯µ¹±â¿°, ±Þ¼º À¶ÇÕ¼º À¯µ¹±â¿°
  • acute colonic obstruction
    ±Þ¼º °áÀå Æó¼â
  • acute conjunctivitis
    ±Þ¼º °á¸·¿°
  • acute coryza
    ±Þ¼º ºñ¿°
  • acute dacryocystitis
    ±Þ¼º ´«¹°ÁÖ¸Ó´Ï ¿°Áõ, ±Þ¼º ´©³¶¿°
    ºñ·ç°üÀÇ »ó, ÇÏ´Ü ¾çÀÚÀÇ ÀϺΠ¶Ç´Â ¿ÏÀüÆó»ö¿¡ ÀÇÇØ »ç°­Çü¼ºÀÌ »ý±èÀ¸·Î½á ÀÏÀ¸Å²´Ù. ¸¸¼º´©³¶¿°¿¡ ÀÇÇØ Áö¼ÓÀûÀ¸·Î ¿°ÁõÀÌ ÀÖÀ¸¸é Á¾Ã¢ÀÌ »ý±â°í ÀÌ ºÎÀ§¿¡¼­ Æó»öÀÌ »ý±ä´Ù. ÀÌ »ç°­³»¿¡¼­ ¿°Áõº´¼Ò´Â ºÎÇ®¾î ¿Ã¶ó¼­ ÁÖÀ§¸¦ ¾Ð¹ÚÇÑ´Ù. ±Þ¼º´©³¶¿°À» ±ÙÄ¡½ÃŰ·Á¸é ´©³¶ÀûÃâ¼ú, ¶Ç´Â ºñ·ç¹®ÇÕ¼úÀ» ÇàÇÑ´Ù. ±â¿°±ÕÀ¸·Î¼­ Æ÷µµ±¸±Õ, Æó·Å±¸±ÕÀÌ ÀÖ°í ºñ·ç°üÀÇ »óÇÏ´Ü Æó»öÀ» ÀÏÀ¸Å°´Â ¿Ü»ó ¶Ç Çü¼ÍºÎÀüÁõ, ÇØºÎÇÐÀû ÀÌ»óµµ ¿øÀÎÀÌ µÈ´Ù.
  • acute delirium
    ±Þ¼º Çê¼Ò¸®, ±Þ¼º ¼¶¸Á
  • acute demyelinating disease
    ±Þ¼º Å»¼öÃʼº Áúȯ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
antinematodal agent Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
(12 Dec 1998)
antineoplastic agent Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells.
(12 Dec 1998)
antineoplastic agent, alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood.
(12 Dec 1998)
antineoplastic agent, combined The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
(12 Dec 1998)
antineoplastic agent, hormonal Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias.
(12 Dec 1998)
antineoplastic agent, phytogenic Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
(12 Dec 1998)
antipsychotic agent A functional category of neuroleptic drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders (e.g., chlorpromazine, haloperidol).
See: neuroleptic.
Synonym: antipsychotic, major tranquilliser.
(05 Mar 2000)
antithyroid agent <pharmacology> Medications which suppress thyroid function.
Examples include methimazole and propylthiouracil.
(13 Jan 1998)
bacteriostatic agent Any agent that inhibits or retards bacterial growth.
Synonym: bacteriostatic agent.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á